RESUMO
OBJECTIVE: To describe clinical effectiveness of belimumab for systemic lupus erythematosus (SLE) in real-world practice in Argentina. METHODS: This retrospective, observational study analysed medical record data of patients with SLE treated with belimumab in 15 centres in Argentina. Primary endpoint: overall clinical response (assessed on a scale similar to the 6-point Physician Global Assessment) at months 6, 12, 18 and 24, all versus index (belimumab initiation). Secondary endpoints: improvement in disease activity (SELENA-SLEDAI), SLE manifestations, and corticosteroid dose change. RESULTS: Records for 81 patients (91% female) were analysed. Clinical improvements were reported for 95%, 95%, 98% and 100% patients at 6, 12, 18, and 24 months post index, respectively. Mean SELENA-SLEDAI score decreased from 11.21 at index to 4.76, 3.77, 3.86 and 2.17 at 6, 12, 18, and 24 months post index, respectively. Number of flares decreased from 1.05 at index to 0.21, 0.09, 0.22 and 0.30 at 6, 12, 18, and 24 months post index, respectively. Mean corticosteroid dose was 14.59 mg/day at index, and 6.45, 5.18, 5.17 and 4.78 mg/day at 6, 12, 18, and 24 months post index, respectively. CONCLUSIONS: Real-world patients with SLE treated with belimumab in Argentina demonstrated clinical improvements and reductions in corticosteroid dose.
Assuntos
Corticosteroides/administração & dosagem , Anticorpos Monoclonais Humanizados/administração & dosagem , Imunossupressores/administração & dosagem , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Resultado do Tratamento , Adulto , Argentina , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Índice de Gravidade de DoençaRESUMO
La fibromialgia (FM)es una afeccion cronica de etiologia desconocida. Los trastornos del sueño estan presentes en la mayoria de los pacientes y su estudio fue motivo del presente trabajo. Se realizo polisomnografia (PSG) en el laboratorio del sueño de nuestro hospital a 22 pacientes con diagnostico de FM, segun criterio del American college of Rheumatology (ACR) 1990. Resultados: Trastornos del sueño (100 por ciento), intrusion alfa-deta (75 por ciento), latencia No REM aumentada (75 por ciento), latencia REM disminuida (60 por ciento), eficiencia del sueño (75 por ciento), fragmentacion del sueño (75 por ciento). Conclusion: Los pacientes con FM presentan marcados disturbios del sueño y una alta incidencia de sueño alfa-delta en el EEG No REM